Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kringle Pharma's Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円-804.88 Mil. Therefore, Kringle Pharma's EV-to-EBIT ratio for today is -2.25.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Kringle Pharma's Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円-804.88 Mil. Therefore, Kringle Pharma's EV-to-EBITDA ratio for today is -2.25.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Kringle Pharma's Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円342.21 Mil. Therefore, Kringle Pharma's EV-to-Revenue ratio for today is 5.30.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Kringle Pharma's Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.00 Mil. Therefore, Kringle Pharma's EV-to-FCF ratio for today is .
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Kringle Pharma (TSE:4884) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Kringle Pharma's current Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-804.88 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Kringle Pharma's current Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-804.88 Mil.
Kringle Pharma's current Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円342.21 Mil.
Kringle Pharma's current Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.
Kringle Pharma's current Enterprise Value is 円1,812.57 Mil.
Kringle Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kringle Pharma Enterprise Value Related Terms
Kringle Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Kringle Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4884 vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Kringle Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kringle Pharma Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kringle Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Kringle Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Kringle Pharma's Enterprise Value for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of 円1,812.57 Mil mean?
Kringle Pharma (TSE:4884) has a Enterprise Value of 円1,812.57 Mil as of Aug. 18, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Kringle Pharma and its competitors.
Is Kringle Pharma's Enterprise Value too high?
Kringle Pharma's current Enterprise Value is 円1,812.57 Mil. Overall, Kringle Pharma has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kringle Pharma's Enterprise Value compare to VRTX and REGN?
Kringle Pharma's Enterprise Value of 円1,812.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Kringle Pharma and its competitors. Kringle Pharma's current Enterprise Value is 円1,812.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kringle Pharma stock overvalued right now?
Based on GuruFocus' analysis, Kringle Pharma (TSE:4884) is currently considered Modestly Undervalued. The stock's GF Value™ is 円481.75, compared to a current price of 円421.00 — trading 12.6% below its estimated fair value. The current Enterprise Value is 円1,812.57 Mil. Kringle Pharma's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Kringle Pharma (TSE:4884), the current Enterprise Value is 円1,812.57 Mil as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kringle Pharma (TSE:4884) Overvalued in 2026?
Based on GuruFocus' analysis, Kringle Pharma stock appears to be undervalued.
The current stock price of 円421.00 is trading 12.6% below its estimated GF Value™ of 円481.75.
GuruFocus considers Kringle Pharma to be Modestly Undervalued.
Key valuation signals for TSE:4884:
Enterprise Value: 円1,812.57 Mil
GF Value™: 円481.75 vs. price of 円421.00 (12.6% below fair value)
No single metric tells the full story. See the TSE:4884 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases. The Company operates in a single segment, pharmaceutical development.
47GF Score
Get the complete analysis for TSE:4884
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4884 has been successfully added to your 
